Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    Sareum Holdings

    MCap

    GBP28m

    Last close

    GBP0.27

    ▲ 6.25 (30.49%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Sequana Medical – Executive Interview

Sequana Medical – Executive Interview

Sequana Medical — 3 videos in collection

More on this equity

Based in Belgium, Sequana Medical develops and commercialises products to treat diuretic-resistant fluid overload, a frequent complication of liver disease and heart failure. Its proprietary alfapump and DSR approaches aim to provide significant clinical and quality-of-life benefits in these fluid overload conditions.

In this interview, chief executive officer Ian Crosbie describes the recently reported positive efficacy data from its POSEIDON North American registration study for the alfapump device in recurrent and refractory ascites, and the next steps planned prior to commercialisation in the region. Mr Crosbie also highlights the company’s recent activities and the upcoming development strategy for its DSR 2.0 product, which is being advanced to treat fluid overload in heart failure patients.

< Previous
Next >

You may also be interested in these:

Healthcare

Sequana Medical - executive interview

Healthcare

Sequana Medical – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free